Fibrocell Science, Inc./University of California, Los Angeles (UCLA) Study on the Generation of Clinical Grade iPS Cells Yields Promising Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
EXTON, Penn.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), announced today positive results from a study demonstrating a potential mechanism for converting research-grade adult skin cells into clinical grade induced pluripotent stem (iPS) cells. The study, entitled “Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status” will be published in the peer-reviewed journal Stem Cell Research and Therapy. The provisional paper is available online at http://stemcellres.com/content/4/4/87/abstract. The study was conducted under the guidance of James Byrne, Ph.D., assistant professor, UCLA Department of Molecular and Medical Pharmacology, at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.
Help employers find you! Check out all the jobs and post your resume.
EXTON, Penn.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), announced today positive results from a study demonstrating a potential mechanism for converting research-grade adult skin cells into clinical grade induced pluripotent stem (iPS) cells. The study, entitled “Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status” will be published in the peer-reviewed journal Stem Cell Research and Therapy. The provisional paper is available online at http://stemcellres.com/content/4/4/87/abstract. The study was conducted under the guidance of James Byrne, Ph.D., assistant professor, UCLA Department of Molecular and Medical Pharmacology, at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.
Help employers find you! Check out all the jobs and post your resume.